Pharmaceutical delivery system
    3.
    发明申请
    Pharmaceutical delivery system 审中-公开
    药物输送系统

    公开(公告)号:US20050095245A1

    公开(公告)日:2005-05-05

    申请号:US10944416

    申请日:2004-09-20

    CPC分类号: A61K9/0036 A61K9/0034

    摘要: A pharmaceutical formulation to treat vaginal conditions in a human patient comprises: at least one active agent; a modified release dosage form which provides extended release of the anti-infective agent upon vaginal administration to the patient; and wherein the formulation, when containing a total dose of the anti-infective agent of about 25 μg to about 500 mg based on the active agent will produce a plasma concentration versus time curve (ng/mL versus hours) having an area under the curve (AUC) of less than about 600 ng/mL.hr.

    摘要翻译: 用于治疗人类患者的阴道病症的药物制剂包括:至少一种活性剂; 一种改良释放剂型,其在阴道给药时提供对抗感染药物的延长释放; 并且其中当基于活性剂含有约25至约500mg的总剂量的抗感染剂时,制剂将产生具有曲线下面积的血浆浓度对时间曲线(ng / mL对小时) (AUC)小于约600ng / mL.hr。

    DRUG DELIVERY SYSTEM
    5.
    发明申请
    DRUG DELIVERY SYSTEM 审中-公开
    药物递送系统

    公开(公告)号:US20070154516A1

    公开(公告)日:2007-07-05

    申请号:US11617199

    申请日:2006-12-28

    摘要: A pharmaceutical composition comprises a first active (e.g., antibacterial) agent and a second (e.g., antifungal) active agent, and comprises a component that is adapted for bioadhesion to a vulvovaginal surface. The composition provides differential release of the active agents at such a surface, wherein the second active agent exhibits a release profile that is substantially delayed, extended and/or inverted relative to the release profile of the first active agent.

    摘要翻译: 药物组合物包含第一活性(例如抗细菌剂)和第二(例如抗真菌)活性剂,并且包含适于生物粘附到外阴阴道表面的组分。 组合物在这样的表面提供活性剂的差异释放,其中第二活性剂表现出相对于第一活性剂的释放曲线基本上延迟,延伸和/或翻转的释放特性。

    Composition for topical treatment of mixed vaginal infections
    6.
    发明申请
    Composition for topical treatment of mixed vaginal infections 审中-公开
    用于局部治疗混合性阴道感染的组合物

    公开(公告)号:US20060140990A1

    公开(公告)日:2006-06-29

    申请号:US11326979

    申请日:2006-01-05

    IPC分类号: A61K31/7034 A61K9/00

    摘要: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.

    摘要翻译: 药物组合物包含(a)抗菌活性量的抗菌剂,例如包括克林霉素或其药学上可接受的盐或酯,和(b)抗真菌有效量的抗真菌剂,例如包括布可康唑或其药学上可接受的盐或 的酯。 该组合物适用于以外阴阴道表面的单位剂量施用,并且具有至少一个非脂性内相和至少一个与外阴阴道表面生物粘附的脂质外相。 该组合物可用于给予外阴阴道表面以治疗混合的细菌性阴道炎和外阴阴道念珠菌病感染。

    COMPOSITION AND METHOD OF USE THEREOF
    7.
    发明申请
    COMPOSITION AND METHOD OF USE THEREOF 审中-公开
    组合物及其使用方法

    公开(公告)号:US20070224226A1

    公开(公告)日:2007-09-27

    申请号:US11617180

    申请日:2006-12-28

    IPC分类号: A61K9/00 A61K31/4172

    摘要: A pharmaceutical composition comprises (a) metronidazole in an antibacterially effective amount; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.

    摘要翻译: 药物组合物包含(a)抗菌活性量的甲硝唑; 和(b)抗真菌有效量的抗真菌剂,例如包括布康唑或其药学上可接受的盐或酯。 该组合物适用于以外阴阴道表面的单位剂量施用,并且具有至少一个非脂性内相和至少一个与外阴阴道表面生物粘附的脂质外相。 该组合物可用于给予外阴阴道表面以治疗混合的细菌性阴道炎和外阴阴道念珠菌病感染。